SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that the company has initiated Phase 2 testing of Interleukin 21 (IL-21) in combination with Nexavar® (sorafenib) tablets in patients with advanced renal cell cancer. The Phase 2 study is part of a Phase 1/2 clinical trial and will examine patients treated with the maximum tolerated dose identified in the recently completed Phase 1 dose escalation phase.
